Skip to main content
Innate Pharma logo

Innate Pharma — Investor Relations & Filings

Ticker · IPH ISIN · FR0010331421 LEI · 9695002Y8420ZB8HJE29 PA Manufacturing
Open in API
Filings indexed 1,406 across all filing types
Latest filing 2020-10-13 Foreign Filer Report
Country FR France
Listing PA IPH

About Innate Pharma

http://www.innate-pharma.com/

Innate Pharma is a clinical-stage, oncology-focused biotechnology company that develops immunotherapies for cancer patients. The company's scientific approach is centered on leveraging the innate immune system, particularly Natural Killer (NK) cells, to create novel treatments. Its innovative pipeline is composed of antibody-based therapeutics, including first-in-class monoclonal antibodies, antibody-drug conjugates (ADCs), and multi-specific NK cell engagers based on its proprietary ANKET® platform. Key clinical programs include lacutamab (anti-KIR3DL2), monalizumab (anti-NKG2A) in partnership with AstraZeneca, and a portfolio of NK cell engagers targeting various hematological malignancies and solid tumors.

Recent filings

Filing Released Lang Actions
FORM 6-K
Foreign Filer Report
2020-10-13 English
NOUVEAU NOMBRE D’ACTIONS ET DE DROITS DE VOTE D’INNATE PHARMA AU 1ER OCTOBRE 2020
Share Issue/Capital Change Classification · 95% confidence The document is titled "NOUVEAU NOMBRE D'ACTIONS ET DE DROITS DE VOTE D'INNATE PHARMA AU 1ER OCTOBRE 2020" (New number of shares and voting rights as of October 1, 2020). It explicitly states that it is published in accordance with French Commercial Code and AMF regulations to report the total number of shares and voting rights as of a specific date. This type of mandatory disclosure regarding the capital structure and voting rights is a specific regulatory filing, but it does not fit perfectly into the standard US SEC forms (like 10-K, ER, etc.). It relates directly to the company's share structure and voting power. Among the provided options, this content is most closely related to announcements concerning capital structure changes or major shareholding notifications. Since it is a formal announcement detailing the exact number of shares and voting rights, it is a specific type of capital/share structure update. The closest fit among the provided codes is 'SHA' (Share Issue/Capital Change) or potentially 'MRQ' (Major Shareholding Notification) if it were crossing a threshold, but since it's a routine update on the total capital base, 'SHA' is the most appropriate classification for a capital structure disclosure, even if it's not a new issuance. Given the context of mandatory regulatory reporting on share count, it is a direct capital structure announcement.
2020-10-13 French
Number of Shares and Voting Rights of Innate Pharma as of October 1, 2020
Share Issue/Capital Change Classification · 95% confidence The document is titled "NUMBER OF SHARES AND VOTING RIGHTS OF INNATE PHARMA AS OF OCTOBER 1, 2020" and explicitly states it is released pursuant to French commercial code and AMF regulations to report the total number of shares outstanding and voting rights as of a specific date (October 1, 2020). This type of periodic disclosure regarding share capital structure and voting rights, often mandated by local regulators (like the AMF in France), does not fit neatly into the primary financial reporting categories (10-K, IR, ER). It is a specific regulatory disclosure concerning share capital. While it relates to capital structure, it is a mandatory periodic update rather than a financing event (CAP) or a general share transaction report (POS). Given the options, this specific, mandatory disclosure of share count and voting rights is best categorized as a general Regulatory Filing (RNS), as it is a required regulatory announcement that doesn't match the more specific definitions like Director's Dealing, Major Shareholding Notification, or Capital Change announcements, which usually relate to transactions or structural changes rather than routine periodic counts.
2020-10-13 English
FORM 6-K
Foreign Filer Report
2020-09-08 English
Innate Pharma présente ses résultats financiers et l'avancée de son portefeuille au premier semestre 2020
Earnings Release Classification · 100% confidence The document is titled "INNATE PHARMA PRÉSENTE SES RÉSULTATS FINANCIERS ET L'AVANCÉE DE SON PORTEFEUILLE AU PREMIER SEMESTRE 2020" and explicitly states: "Innate Pharma SA (...) annonce aujourd'hui ses résultats financiers consolidés pour le premier semestre 2020." It contains detailed financial tables comparing H1 2020 results to H1 2019, including revenue, operating expenses, net loss, and per-share data. The content is a comprehensive report covering a specific interim period (first semester/half-year). This aligns perfectly with the definition of an Interim / Quarterly Report (IR). Although it is a press release format, the core content is the detailed financial report for the period, not just a brief announcement of results (ER) or a general regulatory filing (RNS). H1 2020
2020-09-08 French
Innate Pharma reports first half 2020 financial results and business update
Earnings Release Classification · 100% confidence The document is titled "INNATE PHARMA REPORTS FIRST HALF 2020 FINANCIAL RESULTS AND BUSINESS UPDATE" and explicitly states that it reports "consolidated financial results for the six months ended June 30, 2020." It contains detailed financial highlights, comparative tables for the six-month period, and pipeline updates. This structure is characteristic of a comprehensive financial report covering a period shorter than a full year. Therefore, it fits the definition of an Interim / Quarterly Report (IR). Although it mentions a conference call and presentation, the core content is the financial results themselves, not just the announcement of the report (which would be RPA/RNS). H2 2020
2020-09-08 English

Browse filings by year

19 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.